Evaluating a new biomarker for early kidney injury detection
Homburg Renal Evaluation Study on the Clinical Utility of Early AKI Diagnosis
This study is testing if a new urine test can help doctors spot early signs of kidney injury in critically ill patients before traditional tests do.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universität des Saarlandes Academic / other |
| Locations | 1 site (Homburg, Saarland) |
| Trial ID | NCT06180551 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on critically ill patients at high risk of acute kidney injury (AKI) to assess the clinical utility of urinary dickkopf-3 (uDKK3) as an early predictor of kidney dysfunction. By monitoring patients in the intensive care unit at Saarland University Hospital, the study aims to determine if uDKK3 can provide earlier indications of AKI compared to traditional markers like creatinine. The progression of kidney function will be tracked over a period of up to two years, allowing for a comprehensive evaluation of this biomarker's effectiveness.
Who should consider this trial
Good fit: Ideal candidates for this study are critically ill patients admitted to the intensive care unit at Saarland University Hospital.
Not a fit: Patients with pre-existing chronic kidney disease, those on renal replacement therapy, or those with known kidney diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and intervention for acute kidney injury, potentially improving patient outcomes.
How similar studies have performed: While the use of biomarkers for kidney injury detection is an evolving field, this specific approach using uDKK3 is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients treated on the intensive care units of Saarland University Hospital. Exclusion Criteria: * Patients on renal replacement treatment before admission to the intensive care unit. * Patients with chronic kidney disease stage CKD G3b or below. * Known kidney disease. * Kidney transplantation. * Intoxications leading to dialysis treatment. * Participation in other clinical trials.
Where this trial is running
Homburg, Saarland
- Universitätsklinikum des Saarlandes — Homburg, Saarland, Germany (Recruiting)
Study contacts
- Principal investigator: Stefan Neuhaus, MD — Universität des Saarlandes
- Study coordinator: Stefan Neuhaus, MD
- Email: stefan.neuhaus@uks.eu
- Phone: +4968411615041
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.